Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?

Int J Mol Sci. 2021 May 18;22(10):5313. doi: 10.3390/ijms22105313.

Abstract

Dopamine is a neurotransmitter that mediates neuropsychological functions of the central nervous system (CNS). Recent studies have shown the modulatory effect of dopamine on the cells of innate and adaptive immune systems, including Th17 cells, which play a critical role in inflammatory diseases of the CNS. This article reviews the literature data on the role of dopamine in the regulation of neuroinflammation in multiple sclerosis (MS). The influence of dopaminergic receptor targeting on experimental autoimmune encephalomyelitis (EAE) and MS pathogenesis, as well as the therapeutic potential of dopaminergic drugs as add-on pathogenetic therapy of MS, is discussed.

Keywords: Th17 cells; dopamine; multiple sclerosis; neuroinflammation; psychoneuroimmunology.

Publication types

  • Review

MeSH terms

  • Animals
  • Dopamine / immunology*
  • Dopamine / physiology
  • Dopamine Agents / pharmacology
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Encephalomyelitis, Autoimmune, Experimental / physiopathology
  • Humans
  • Mice
  • Models, Immunological
  • Models, Neurological
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / physiopathology
  • Neuroimmunomodulation / drug effects
  • Neuroimmunomodulation / immunology
  • Neuroimmunomodulation / physiology
  • Receptors, Dopamine / drug effects*
  • Receptors, Dopamine / immunology
  • Receptors, Dopamine / physiology
  • Th17 Cells / drug effects
  • Th17 Cells / immunology

Substances

  • Dopamine Agents
  • Receptors, Dopamine
  • Dopamine